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Introduction
Most cancers have large hypoxic regions, 
which display an increase of the glycolytic 
metabolism leading to the production of lactate, 
providing cancer cells with adequate amounts 
of energy and anabolites. To this end, tumor 
cells generally overexpress glucose transporters 
(GLUTs), in particular GLUT1, which results 
in an increased uptake of glucose to support 
their less efficient energy production (Warburg 
effect). Therefore, therapeutic interventions 
aimed at reducing cancer glycolysis may be 
implemented by several strategies, including 
the development of inhibitors of glucose 
transporters. Furthermore, extracellular matrix 
(ECM) remodeling is one of the key processes 
preluding metastatic invasion, and it is 
promoted by several effectors, such as lysyl 
oxidase (LOX), an enzyme commonly involved 
in extracellular matrix maturation. LOX is up-
regulated by HIF-1 and plays a critical role in 
the development of metastasis. Therefore, LOX 
inhibitors may represent an additional and 
innovative strategy for the treatment and the 
prevention of metastatic cancer.
Methods
We have developed various classes of 
compounds that are able to interfere with 
GLUTs (Granchi et al. 2015, Tuccinardi et al. 
2013) and LOX (Granchi et al. 2009) by 
molecular design and chemical synthesis. Their 
effect on cell proliferation, apoptosis, migration 
and other key determinants of activity were 
evaluated by sulforhodamine-B and luciferase 
assays, FACS, wound-healing assay, and 
Quantitative PCR. The studies were performed 
in seven PDAC cells, including five primary-
cell-cultures and 3D co-cultures with human 
stellate cells, in normoxic and hypoxic 
conditions.
Results
The IC50s of the tested compounds ranged from 
13.9 to 32.0 μM after 72-hour exposure. 
Notably, these compounds were still active in 
3D co-cultures of these tumor cells with 
pancreatic stellate cells, which showed 
increased resistance to gemcitabine and are 
more representative of the dense stromal 
compartment with core hypoxic areas of this 
tumor type, as detected by 
immunohistochemical stainings. Remarkably, 
one compound (PGL-14) showed a synergistic 
interaction with gemcitabine, increasing 
apoptosis induction and accumulation of ROS. 
Furthermore, the combination of these drugs 
reduced cell migration and enhanced in vitro 
sensitivity to anoikis, suggesting the ability of 
these compounds to inhibit metastasis.
Discussion
GLUT1 inhibitors were more active in hypoxia, 
but still active also in normoxia. Conversely, 
we did not detect cytotoxic effects using the 
LOX-inhibitors in normoxia (at concentration 
until 50 μM) since they were designed as 
bioreductively activated prodrugs, which are 
therefore activated only under hypoxic 
conditions. However, at O2 tension of 1%, 
IC50s were below 10 μM.  As reported 
previously, LOX inhibition was associated with 
reduction of the mRNA levels of fibronectin, 
suggesting that it might also have impact on the 
interaction of tumor cells with the stroma that 
are mediated by integrins and fibronectin, 
regulating tissue stiffness (Coppola et al. 2017) .
Conclusion
Interventions aimed at blocking the glycolytic 
activity or the extracellular matrix remodeling 
of tumors by means of newly designed 
molecules proved to exert a synergistic effect 
with clinically approved drugs, such as 
gemcitabine. These results seem to support the 
strategy of the simultaneous GLUT/LOX-
inhibition in order to further sensitize hypoxic 
cancer portions to chemotherapy.
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